CONMED Corporation (NYSE:CNMD - Get Free Report)'s share price passed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $47.21 and traded as low as $45.31. CONMED shares last traded at $46.33, with a volume of 437,111 shares traded.
Analyst Ratings Changes
CNMD has been the subject of a number of recent research reports. Wells Fargo & Company boosted their price objective on CONMED from $46.00 to $49.00 and gave the company an "equal weight" rating in a research note on Thursday, October 29th. Zacks Research raised CONMED from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 11th. Piper Sandler restated a "neutral" rating and set a $45.00 price target (up from $39.00) on shares of CONMED in a report on Thursday, July 30th. Weiss Ratings raised CONMED from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday, November 4th. Finally, JPMorgan Chase & Co. upped their price objective on CONMED from $45.00 to $50.00 and gave the stock a "neutral" rating in a report on Thursday, October 29th. Seven investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Reduce" and an average price target of $44.00.
Read Our Latest Stock Report on CONMED
CONMED Trading Down 3.5%
The company has a quick ratio of 0.70, a current ratio of 1.49 and a debt-to-equity ratio of 0.60. The firm has a market cap of $1.38 billion, a P/E ratio of 19.14, a P/E/G ratio of 2.23 and a beta of 0.90. The company's 50 day simple moving average is $47.21 and its 200-day simple moving average is $42.11.
CONMED (NYSE:CNMD - Get Free Report) last issued its earnings results on Wednesday, October 28th. The company reported $1.04 EPS for the quarter, topping analysts' consensus estimates of $1.00 by $0.04. CONMED had a net margin of 5.36% and a return on equity of 13.93%. The business had revenue of $335.56 million for the quarter, compared to the consensus estimate of $336.28 million. During the same period in the prior year, the firm earned $1.08 EPS. The company's revenue for the quarter was down .7% compared to the same quarter last year. As a group, research analysts predict that CONMED Corporation will post 4.58 earnings per share for the current fiscal year.
Institutional Trading of CONMED
Institutional investors have recently bought and sold shares of the stock. Illinois Municipal Retirement Fund grew its stake in CONMED by 1.3% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 16,492 shares of the company's stock valued at $762,000 after purchasing an additional 215 shares during the last quarter. Signaturefd LLC raised its stake in shares of CONMED by 82.7% in the third quarter. Signaturefd LLC now owns 548 shares of the company's stock worth $25,000 after purchasing an additional 248 shares during the last quarter. Choreo LLC raised its stake in shares of CONMED by 3.0% in the third quarter. Choreo LLC now owns 16,571 shares of the company's stock worth $766,000 after purchasing an additional 480 shares during the last quarter. Moore Capital Management LP lifted its holdings in shares of CONMED by 2.6% during the second quarter. Moore Capital Management LP now owns 25,230 shares of the company's stock worth $826,000 after purchasing an additional 651 shares during the period. Finally, PNC Financial Services Group Inc. boosted its position in CONMED by 29.5% in the first quarter. PNC Financial Services Group Inc. now owns 3,085 shares of the company's stock valued at $109,000 after buying an additional 703 shares during the last quarter.
CONMED Company Profile
(
Get Free Report)
CONMED Corporation is a medical technology company that develops and markets devices and equipment for orthopedic and general surgery. Its products support minimally invasive procedures and include arthroscopy systems, powered surgical instruments, electrosurgical equipment, and endoscopic technologies. The company was founded in 1970 and serves hospitals, surgery centers, and other healthcare providers. Its products are sold in the United States and internationally.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CONMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CONMED wasn't on the list.
While CONMED currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.